About Meril Life Sciences Private Limited
Data last updated: 20 December 2025
Meril Life Sciences Private Limited is a private limited company based in Vapi, Gujarat, India, a subsidiary of Micro Life Sciences Private Limited. It specialises in medical and laboratory equipment, a part of the broader healthcare sector. Incorporated on 19 June 2007, the company has been in operation for over 19 years.
Registered with ROC Ahmedabad under CIN U24239GJ2007PTC051137.
Capital: an authorised share capital of ₹100 Cr and a paid-up capital of ₹99.36 Cr. It is led by directors including Nanubhai Premjibhai Bambharolia and Rajnikant Gandalal Vyas.
Last AGM: 30 July 2025. Financial statements filed for year ended 31 March 2025. Office: Bilakhia House Survey No. 135/139 Muktanand Marg Chala, Vapi, Gujarat, India – 396191.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,729.52 Cr, a growth of 44% compared to the previous year.
The company has a workforce of approximately 1,584 employees as per the latest available data. It operates as a subsidiary of Micro Life Sciences Private Limited. Its group structure includes 1 subsidiary.
The company is associated with 4 brands - Myval, Misso, Merilvet, Meril. As per MCA filings, the company has open charges of ₹788.45 Cr and satisfied charges of ₹228.76 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website merillife.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressBilakhia House Survey No. 135/139 Muktanand Marg Chala, Vapi, Gujarat, India – 396191
-
IndustryHealthcare, Medical & Laboratory Equipment
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Meril Life Sciences Private Limited
Meril Life Sciences Private Limited operates multiple associated brands including Myval, Misso, and Merilvet. These brands represent Meril Life Sciences Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers a transcatheter aortic heart valve replacement system. | myval.com | |
| MISSO provides robotic assistance for accurate joint replacements using 3D scans. | misso.ai | |
| Medical device innovation in orthopedics, endo-surgery, and diagnostics. | merilvet.com | |
| Developer of medical devices for surgeries and diagnosis | merillife.com |
Competitors & Alternatives of Meril Life Sciences Private Limited
Brands and companies operating in the same space as Meril Life Sciences Private Limited include GE Healthcare, Medtronic, Boston Scientific and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
GE Healthcare
|
Materials management solutions are provided for healthcare organizations. | Chicago, United States, United States | 1892 |
Medtronic
|
Medical equipment for treating over 30 chronic diseases is developed. | Minneapolis, United States, United States | 1949 |
Boston Scientific
|
Wide range of medical devices | Marlborough, United States, United States | 1979 |
Johnson & Johnson
|
Healthcare solutions are provided by Johnson & Johnson globally. | New Brunswick, United States, United States | 1886 |
Silk Road Medical
|
Provider of neuroprotection devices for carotid artery disease | Sunnyvale, United States, United States | 2007 |
Hologic
|
Diagnostic and surgical products for women's healthcare are provided. | Marlborough, United States, United States | 1985 |
CONMED
|
Surgical instruments are manufactured for multiple therapeutic areas. | Utica, United States, United States | 1987 |
Commure
|
Complex healthcare challenges are addressed through technology solutions by Commure. | San Francisco, United States, United States | 2016 |
Coherent
|
Laser-based and photonics products are manufactured for multiple applications. | Santa Clara, United States, United States | 1966 |
Baxter
|
Biosciences, medication delivery, and renal products are developed and marketed. | Deerfield, United States, United States | 1931 |
Business Activity of Meril Life Sciences Private Limited
Meril Life Sciences Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C13 | Other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities | ********* |
Auditor Details of Meril Life Sciences Private Limited
Meril Life Sciences Private Limited is audited by DELOITTE HASKINS & SELLS LLP for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| DELOITTE HASKINS & SELLS LLP | blur-value | blur-value | blur-value |
Board of Directors of Meril Life Sciences Private Limited
Meril Life Sciences Private Limited is currently managed by 4 directors, with 9 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Nanubhai Premjibhai Bambharolia
Also directs:
Maxwell Eco-Green Private Limited, Milestone Holdings & Infrastructure Private Limited, Mitsu Private Limited and 1 more
|
Whole-Time Director | 19 Jun 2007 | 19 Years 0 Months | Current |
|
Rajnikant Gandalal Vyas
Also directs:
Meril Diagnostics Private Limited, Meril Endo Surgery Private Limited, Mapel Infrastructure Private Limited and 2 more
|
Whole-Time Director | 20 Oct 2010 | 15 Years 8 Months | Current |
| Hemchandra Yadunandan Panjikar | Director | 11 Mar 2023 | 3 Years 3 Months | Current |
Financials of Meril Life Sciences Private Limited FY 2025 filings available
Meril Life Sciences Private Limited reported revenue of ₹1,729.52 Cr (up 44% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Meril Life Sciences Private Limited
As of FY 2022, Meril Life Sciences Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Meril Life Sciences Private Limited
Meril Life Sciences Private Limited has 1 subsidiary company. This group structure data is as of FY 2022. The corporate group structure reflects Meril Life Sciences Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Meril Life Sciences India Private Limited | U33110GJ1999PTC060787 |
**.**%
|
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Meril Life Sciences Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Nov 2024 | Others | ₹144 Cr | Open |
| 13 Jun 2023 | Others | ₹146 Cr | Open |
| 28 Sep 2021 | Others | ₹110 Cr | Open |
| 25 Jun 2019 | Hdfc Bank Limited | ₹120 Cr | Open |
| 07 Jun 2019 | Others | ₹20 Cr | Open |
Total charge records: 15 View all charges
Employees and EPFO Compliance at Meril Life Sciences Private Limited
Meril Life Sciences Private Limited has a workforce of 1,584 employees as of Sep 25, 2025.
Employee Count & EPFO Data of Meril Life Sciences Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Meril Life Sciences Private Limited
GSTIN & GST Filing Data of Meril Life Sciences Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Meril Life Sciences Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Meril Life Sciences Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Meril Life Sciences Private Limited
MSME Payment Delays by Meril Life Sciences Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Meril Life Sciences Private Limited
Subsidiaries & Group Companies of Meril Life Sciences Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Meril Life Sciences Private Limited with ownership details.
MCA Filings & Documents of Meril Life Sciences Private Limited
MCA Filings & Documents of Meril Life Sciences Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Meril Life Sciences Private Limited
Recent News on Meril Life Sciences Private Limited
Frequently Asked Questions about Meril Life Sciences Private Limited
Meril Life Sciences Private Limited is an active private limited company in the healthcare sector based in Vapi, Gujarat, India. It was incorporated on 19 June 2007 (19+ years old) and is registered under CIN U24239GJ2007PTC051137. The company has 1,584 employees.
Meril Life Sciences Private Limited reported revenue of ₹1,729.52 Cr for FY 2025 (up 44.00% YoY).
The current directors of Meril Life Sciences Private Limited are:
- Nanubhai Premjibhai Bambharolia
- Rajnikant Gandalal Vyas
- Rushi Jagdish Sathe
- Hemchandra Yadunandan Panjikar
The primary industry of Meril Life Sciences Private Limited is healthcare. The company specifically operates in medical and laboratory equipment. The company is currently active in this sector.
Meril Life Sciences Private Limited can be reached at the registered office: Bilakhia House Survey No. 135139 Muktanand Marg Chala, Vapi, Gujarat, India – 396191, or through the website merillife.com.
The authorised capital is ₹100 Cr, and the paid-up capital is ₹99.36 Cr.